Buy & Sell Fastly Inc (FSLY) – Fastly Inc Price Today
Aura AI Summary
Key Stats
- $2.54BMarket Cap
- TechnologySector
- -51.6%3M Drawdown
- $2.61BEnterprise Value
- -Dividend Yield
- 51% Buy | 49% SellTrading Activity
- 26 daysTypical Hold Time
Fastly Inc (FSLY) is currently valued at a market capitalization of $2.54B, with an enterprise value of $2.61B. Over the past 52 weeks, Fastly Inc has traded between a low of $6.36 and a high of $33.5, highlighting its annual price range. Over the past three months, Fastly Inc has recorded a drawdown of -51.6%, reflecting recent price volatility. On average, investors hold Fastly Inc for approximately 26 days, indicating typical investor behavior on the platform.
About Fastly Inc
Fastly operates a content delivery network, which is necessary for entities to provide faster and more reliable online content. Fastly's strategy differs from traditional CDNs, which focused on locating servers in as many locations as possible to store copies of files that consumers most use. Fastly has far fewer sites than traditional CDNs, but it houses servers in the most network-dense data centers. Instead of simply storing static content, it allows its customers to program on its platform, enabling edge computing and better service of the more dynamic content that was traditionally not well served by CDNs. Fastly gears its service to the largest, most sophisticated enterprises rather than small companies and generated about two thirds of its revenue in the United States in 2020.
Most Recent News
Complex small molecules reshape drug R&D, demanding integrated discovery to manufacturing solutions.
WuXi AppTec highlights how the increasing structural complexity of small molecules, such as targeted protein degraders and covalent inhibitors, is transforming drug research and development. These new molecules require advanced, integrated approaches...
Axsome starts Phase 3 trial of solriamfetol for ADHD in adolescents, aiming to improve treatment options.
Axsome Therapeutics has initiated the FOCUS-3 Phase 3 clinical trial to evaluate solriamfetol as a treatment for adolescents aged 12 to under 18 with ADHD. This randomized, double-blind, placebo-controlled study will enroll about 468 patients to asse...
SoundHound AI's COO sells 65,000 shares, signaling insider stock movement.
SoundHound AI's Chief Operating Officer has sold 65,000 shares of the company's stock. This insider sale could indicate personal financial decisions or a strategic move related to the company's outlook. Investors often watch such transactions closely...
